Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547439 · ClinicalTrials.gov registry record · Phase 2
Sleep, Diabetic Retinopathy and Melatonin
A Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04547439 is a Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 42 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04547439, a Phase 2 study of Diabetes Mellitus and Diabetic Retinopathy, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the use of melatonin in patients with diabetic retinopathy
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Melatonin
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04547439
The ClinicalTrials.gov registry entry for NCT04547439 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (98% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04547439 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04547439 about?
NCT04547439 is a clinical study titled "Sleep, Diabetic Retinopathy and Melatonin". This study explores the use of melatonin in patients with diabetic retinopathy
What is the current status of trial NCT04547439?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2021-02-03. Estimated completion is 2026-06.
What conditions does trial NCT04547439 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Diabetic Retinopathy.
What interventions are being tested in trial NCT04547439?
The interventions under investigation include: Placebo (OTHER), Melatonin (DRUG).
Who is sponsoring clinical trial NCT04547439?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04547439 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia
RECRUITING · Phase 2
-
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus
RECRUITING · Phase 2
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.